Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Ono Extend Drug Discovery Services Pact

NEW YORK (GenomeWeb News) – Evotec and Ono Pharmaceutical have extended a research collaboration and have struck a new agreement to study potential drug compounds, Evotec said today.

The companies began their drug target collaboration in March 2008.

Under the agreements, Evotec will provide high-throughput screening, in vitro pharmacology, protein crystallography, and medicinal chemistry services to discover small molecular weight compounds that will be used against an ion channel target. The aim of the collaboration is to move Ono's compound towards clinical development.

For its research services, Evotec will receive research funding and milestone payments, the Hamburg-based company said.

"We anticipate the collaboration will result in identifying a novel drug candidate with a high potential," Ono's Managing Director, Kazuhito Kawabata, said in a statement.

Specific financial terms of the agreement were not released.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.